Mazicon (flumazenil/Roche).
Flumazenil exerts its effect by competitive inhibition of the benzodiazepine agonist from the receptors in the CNS, thereby blocking the effect of the agonist. Flumazenil, in doses to 1.0 mg intravenously, has been shown in clinical trials to be effective for the complete reversal of benzodiazepine sedation after intravenous conscious sedation or general anesthesia. It is effective even in the presence of other drugs, including opioids. Most patients are aroused and completely alert within a few minutes after the administration of flumazenil and maintained their alertness throughout the 180-min observation period.
Claussen
D
D
D005442:Flumazenil / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D009732:Nursing Care
D005442:Flumazenil